Amgen, Inc. (AMGN) | Stock price, performance, AI analysis | Thematic | AI powered fundamental research and development platform

Loading...

Research a topic Stock screener Find companies

Search for securities Load an existing portfolio Backtest

Thematic overview Develop asset-backed products Company evaluations Backtesting and benchmarking Thematic branded indices

Research a topic Stock screener Find companies

Search for securities Load an existing portfolio Backtest

Thematic overview Develop asset-backed products Company evaluations Backtesting and benchmarking Thematic branded indices

Follow our journey and product updates

Product

Overview Company evaluations Research a topic

Company

About us Blog Contact

Legal

Terms Privacy Policy

Amgen, Inc. (AMGN)

Evaluation: Based on all recent filings, financial statements, and news.

See full evaluation

Ask a question about Amgen, Inc. (AMGN)

Company Performance

Current Price

as of Dec 04, 2024

$278.26

P/E Ratio

35.63

Market Cap

$149.57B

Description

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. It operates through Human Therapeutics segment. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Metrics

Overview

HQThousand Oaks, CA
SectorHealth Technology
IndustryBiotechnology
TickerAMGN
Price$278.26-0.02%

Trading Information

Market cap$149.57B
Float99.74%
Average Daily Volume (1m)4,601,614
Average Daily Volume (3m)2,751,406
EPS$7.88

Company

Revenue$32.32B
Rev growth (1yr)23.11%
Net income$2.83B
Gross margin60.87%
EBITDA margin40.17%
EBITDA$3.40B

EV$226.03B
EV/Revenue6.99
P/E35.63
P/S4.67
P/B19.87

Documents

SEC Filings

8-K (2024-10-30)

8-K (2024-08-06)

8-K (2024-06-03)

8-K (2024-05-02)

8-K (2024-02-06)

8-K (2023-12-14)

8-K (2023-10-31)

8-K (2023-10-06)

8-K (2023-10-05)

8-K (2023-09-12)

8-K (2023-09-05)

8-K (2023-09-01)

8-K (2023-08-04)

8-K (2023-08-03)

8-K (2023-06-05)

8-K (2023-05-22)

8-K (2023-05-18)

8-K (2023-05-16)

8-K (2023-04-27)

8-K (2023-03-09)

8-K (2023-03-02)

8-K (2023-02-16)

8-K (2023-01-31)

10-Q (2024-10-31)

10-Q (2024-08-07)

10-Q (2024-05-03)

10-Q (2023-10-31)

10-Q (2023-08-04)

10-Q (2023-04-28)

10-K (2024-02-14)

10-K (2023-02-09)

Factset Street Account

StreetAccount Consensus Metrics Preview - Amgen Q3 Earnings ($274.23, -1.89) (2023-10-25T16:53:56Z)

Street Takeaways - Amgen Q3 earnings ($264.70, +3.86) (2023-11-02T15:49:23Z)

FDA grants orphan drug designation to AMG 193 for biliary tract cancers ($265.52, 0.00) (2023-11-29T00:00:04Z)

CORRECTION: Street Takeaways - Amgen Q3 earnings ($265.15, +4.31) (2023-11-02T15:07:15Z)

Amgen upgraded to outperform at BMO Capital Markets ($275.48, 0.00) (2023-12-19T09:07:14Z)

Amgen upgraded to buy from hold at Truist ($134.53, 0.00) (2023-11-02T10:04:00Z)

Amgen resumed equal-weight at Morgan Stanley; prior rating was overweight ($286.88, 0.00) (2023-10-17T06:21:36Z)

Amgen presents new LUMAKRAS (sotorasib) plus Vectibix (panitumumab) data in patients with KRAS G12C-mutated mCRC ($278.81, 0.00) (2023-10-22T14:39:57Z)

Amgen new research from Phase 4 FOREMOST study of Otezla in psoriatic arthritis to be presented at ACR 2023; meets primary endpoint ($271.11, 0.00) (2023-11-07T21:30:36Z)

Amgen announces presentation of new data on Repatha, olpasiran at AHA 2023 ($264.06, 0.00) (2023-11-10T14:05:18Z)

Amgen announces presentation of new data from phase 2 trial of dazodalibep in Sjögren's syndrome at ACR 2023 ($271.54, 0.00) (2023-11-07T21:02:01Z)

Amgen announced new data for Krystexxa showing a decrease in blood pressure during treatment of adults living with chronic uncontrolled gout ($260.84, 0.00) (2023-11-02T12:12:23Z)

Wikipedia

Earnings Calls

Earnings Report 2024Q3

Earnings Report 2024Q2

Earnings Report 2024Q1

Earnings Report (2023-10-31)

Earnings Report (2023-08-03)

Factset

Factset Business Description